Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Goodwill (2021 - 2025)

Xeris Biopharma Holdings' Goodwill history spans 5 years, with the latest figure at $22.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Goodwill changed 0.0% year-over-year to $22.9 million, compared with a TTM value of $22.9 million through Dec 2025, changed 0.0%, and an annual FY2025 reading of $22.9 million, changed 0.0% over the prior year.
  • Goodwill for Q4 2025 was $22.9 million at Xeris Biopharma Holdings, roughly flat from $22.9 million in the prior quarter.
  • The five-year high for Goodwill was $22.9 million in Q4 2021, with the low at $22.9 million in Q4 2021.
  • Average Goodwill over 5 years is $22.9 million, with a median of $22.9 million recorded in 2021.
  • Biggest YoY gain for Goodwill was 0.0% in 2022; the steepest drop was 0.0% in 2022.
  • Tracing XERS's Goodwill over 5 years: stood at $22.9 million in 2021, then changed by 0.0% to $22.9 million in 2022, then changed by 0.0% to $22.9 million in 2023, then changed by 0.0% to $22.9 million in 2024, then changed by 0.0% to $22.9 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Goodwill are $22.9 million (Q4 2025), $22.9 million (Q3 2025), and $22.9 million (Q2 2025).